Digoxin is a cardiac glycoside indicated for treatment of mild to moderate heart failure in adults, among other approved uses. It is available as tablets, injection and oral solution for intramuscular and intravenous use. MedsAcross supplies Digoxin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LANOXIN is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. Increasing myocardial contractility in pediatric patients with heart failure. Control of resting ventricular rate in adults with chronic atrial fibrillation.
Source: US FDA prescribing information
All of digoxin’s actions are mediated through its effects on Na-K ATPase. This enzyme, the “sodium pump,” is responsible for maintaining the intracellular milieu throughout the body by moving sodium ions out of and potassium ions into cells.
Source: US FDA prescribing information
LANOXIN dose is based on patient-specific factors (age, lean body weight, renal function, etc.). See full prescribing information. Monitor for toxicity and therapeutic effect. Intravenous administration is preferable to intramuscular. Avoid bolus administration.
Source: US FDA prescribing information
LANOXIN is contraindicated in patients with: Ventricular fibrillation Known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). A hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin. Ventricular fibrillation. Known hypersensitivity to digoxin or other forms of digitalis.
Source: US FDA prescribing information
Risk of rapid ventricular response leading to ventricular fibrillation in patients with AV accessory pathway. Risk of advanced or complete heart block in patients with sinus node disease and AV block. Digoxin toxicity: Indicated by nausea, vomiting, visual disturbances, and cardiac arrhythmias. Advanced age, low body weight, impaired renal function and electrolyte abnormalities predispose to toxicity. Risk of ventricular arrhythmias during electrical cardioversion. Not recommended in patients with acute myocardial infarction. Avoid LANOXIN in patients with myocarditis.
Source: US FDA prescribing information
The following adverse reactions are included in more detail in the Warnings and Precautions section of the label: Cardiac arrhythmias Digoxin Toxicity The overall incidence of adverse reactions with digoxin has been reported as 5-20%, with 15-20% of adverse events considered serious. Cardiac toxicity accounts for about one-half, gastrointestinal disturbances for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse events.
Source: US FDA prescribing information
Digoxin has a narrow therapeutic index, increased monitoring of serum digoxin concentrations and for potential signs and symptoms of clinical toxicity is necessary when initiating, adjusting, or discontinuing drugs that may interact with digoxin. Prescribers should consult the prescribing information of any drug which is co-prescribed with digoxin for potential drug interaction information. PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. The potential for drug-drug interactions must be considered prior to and during drug therapy. See full prescribing information.
Source: US FDA prescribing information
Store at 25 °C (77 °F), excursions permitted to 15 °C to 30 °C (59 °F to 86 °F) and protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
14 presentations of Digoxin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Digoxin 125 mcg tabletOralGeneric name | — | US FDA | Available on request |
| Digoxin 250 mcg tabletOralGeneric name | — | US FDA | Available on request |
| Digoxin 0.5 mg/2 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Digoxin 0.05 mg/mL oral solutionOralGeneric name | — | US FDA | Available on request |
| Digoxin 0.0625 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lanoxin 0.125 mg tabletOral | Advanz Pharma | US FDA | Available on request |
| Digoxin 500 mcg/2 mL injectionIntramuscular, intravenous, parenteralGeneric name | — | US FDA | Available on request |
| Digoxin 0.25 mg/1 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Lanoxin 0.0625 mg tabletOral | Advanz Pharma | US FDA | Available on request |
| Lanoxin 0.25 mg tabletOral | Advanz Pharma | US FDA | Available on request |
| Lanoxin 100 mcg/1 mL injectionIntramuscular, intravenous | Covis Pharma | US FDA | Available on request |
| Lanoxin 500 mcg/2 mL injectionIntramuscular, intravenous | Covis Pharma | US FDA | Available on request |
| Lanoxin 100 mcg/mL injectionIntramuscular, intravenous | Covis Pharma | US FDA | Available on request |
| Lanoxin 250 mcg/mL injectionIntramuscular, intravenous | Covis Pharma | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 16 November 1954 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Digoxin in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 14 presentations of Digoxin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Digoxin, including Lanoxin.
Yes. The US FDA first approved Digoxin on 16 November 1954, according to Drugs@FDA.
No listed presentation of Digoxin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Digoxin is classified under ATC code C01AA05 (Digoxin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.